Recruiting

FIRM Ablation

Sponsor:

Ohio State University

Code:

NCT03444337

Conditions

Atrial Fibrillation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Catheter Ablation

Study Details

Brief summary:

Patients undergoing FIRM guided ablation of atrial fibrillation will undergo high resolution MRI imaging to determine correlation of underlying anatomic fibrotic regions with FIRM targeted sites for ablation.

Conditions

Atrial Fibrillation

Study ID

NCT03444337

Start date

Nov 3, 2016

Status verified date

Sep, 2026

Completion date

Apr 30, 2028

Anticipated

Primary completion date

Dec 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Patients with symptomatic paroxysmal or persistent atrial fibrillation undergoing clinically-indicated ablation procedure employing FIRM mapping with pre-operative MRI.
2. Subjects must be at least 18 years of age.

Exclusion Criteria:

1. LAA thrombus present on pre-procedure TEE
2. Unable to undergo MRI imaging
3. Unable to receive gadolinium contrast.

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

Catheter Ablation Group

Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI

Interventions

Catheter Ablation

Primary outcome measure

  • Correlation of FIRM targeted sites with MRI fibrotic regions [ Time Frame: Immediate post-procedure analysis ]

Central Contacts and Locations

Central contacts

Locations

Ohio State University

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Principal Investigator:

John Hummel, MD

More Information

Sponsor

Ohio State University

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • ablation
  • atrial fibrillation
  • FIRM

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University on 2026-09-09.